Compliance certificate under Regulation 74(5) of SEBI (DP) Regulation, 2018
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Asston Pharmaceuticals Ltd has submitted a routine compliance certificate to BSE for the quarter ended 31 December 2025. The certificate, issued by the company's Registrar and Share Transfer Agent (Maashitla Securities Private Limited), confirms that any securities received from depository participants for dematerialisation during the quarter were properly processed and confirmed to the depositories. It also confirms that share certificates received for dematerialisation were cancelled after verification, and the depository's name was substituted as the registered owner in the company's records within the required 15-day timeline. The filing was signed by Rishi Upadhaya, Company Secretary and Compliance Officer, on 6 January 2026.
This is a standard procedural regulatory filing with no material impact on the business, financials, or share price. It simply confirms the smooth processing of dematerialisation requests during the October–December 2025 quarter and has no bearing on shareholder value.